Pharmacogenetic profiling in the treatment of heart disease.

Translational Research : the Journal of Laboratory and Clinical Medicine
Gerald W Dorn

Abstract

Pharmacogenetics is the study of gene-drug interactions. In the post-Human Genome era, and with the realization that personal genotypes differ by millions of bases (gene polymorphisms), the application of genetics to explain interindividual differences in clinical drug response seems to offer great promise. Here, recent basic and translational developments in pharmacogenetic profiling of beta-blocker response in heart failure are reviewed in the context of the possible consequences of such advances on drug development and clinical therapeutics.

References

Nov 1, 1980·Clinical Pharmacokinetics·C G Regårdh, G Johnsson
Dec 16, 1982·The New England Journal of Medicine·M S LennardH F Woods
Jun 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·P Kunapuli, J L Benovic
Apr 23, 1999·The Journal of Biological Chemistry·D A MasonS B Liggett
Apr 3, 2001·Annals of Internal Medicine·J M BrophyJ L Rouleau
Jun 2, 2001·The New England Journal of Medicine·UNKNOWN Beta-Blocker Evaluation of Survival Trial InvestigatorsPhilip W Lavori
Aug 13, 2002·Pharmacogenetics·Thomas RauThomas Eschenhagen
Oct 19, 2002·Clinical Pharmacology and Therapeutics·Henrike WuttkeThomas Eschenhagen
Oct 19, 2002·Clinical Pharmacology and Therapeutics·Jürgen BrockmöllerIvar Roots
Sep 30, 2003·The American Journal of Psychiatry·Greer M MurphyAlan F Schatzberg
Apr 30, 2004·Clinical Pharmacology and Therapeutics·Peter J Wedlund, Jose de Leon
Nov 16, 2004·Journal of the American College of Cardiology·David M KayeMurray D Esler
Dec 14, 2004·Clinical Pharmacology and Therapeutics·Issam ZinehJulie A Johnson
Oct 4, 2005·Clinical Pharmacology and Therapeutics·Richard FuxKari T Kivistö
Dec 6, 2005·Journal of the American College of Cardiology·Heike BruckOtto-Erich Brodde
Jul 18, 2006·Proceedings of the National Academy of Sciences of the United States of America·Stephen B LiggettMichael R Bristow
Jan 4, 2007·The Journal of Clinical Investigation·Francesca RochaisStefan Engelhardt
Aug 24, 2007·Clinical and Experimental Pharmacology & Physiology·P MolenaarA J Kaumann
Jan 19, 2008·Clinical Pharmacology and Therapeutics·J Kirchheiner
Mar 12, 2008·Journal of Translational Medicine·Michael A PacanowskiJulie A Johnson
Jul 4, 2008·Pharmacogenomics·Gerald W Dorn, Sharon Cresci
Sep 12, 2008·Clinical Pharmacology and Therapeutics·M J BijlB H Ch Stricker
Nov 28, 2008·Clinical Pharmacology and Therapeutics·T RauT Eschenhagen
Apr 29, 2009·Circulation·Dan M Roden, C Michael Stein
Jul 25, 2009·Journal of the American College of Cardiology·Sharon CresciGerald W Dorn

❮ Previous
Next ❯

Citations

Feb 11, 2016·Journal of Molecular and Cellular Cardiology·Miklos D KertaiUNKNOWN Duke Perioperative Genetics and Safety Outcomes (PEGASUS) Investigative Team
Jul 23, 2014·Circulation. Cardiovascular Genetics·Miklos D KertaiUNKNOWN Duke Perioperative Genetics and Safety Outcomes (PEGASUS) Investigative Team
Mar 23, 2011·Nature Reviews. Genetics·Esther E CreemersYigal M Pinto
May 21, 2013·Pharmacological Reviews·Julie A Johnson, Larisa H Cavallari
Mar 27, 2019·International Journal of Molecular Sciences·Julie L Horton, Jitka Virag

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.